Study of the Predictive Marker FLT in Patients Suffering From AML

Acute Myeloid Leukemia Clinical Trial

— TEP-FLT-LMA  

Official title:

Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01599429
• Other study ID #: CIMS-2011-01
• Status: Withdrawn
• Start date: October 31, 2011
• Est. completion date: December 31, 2017

Study information

• Verified date: April 2021
• Source: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.

Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.

The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2017
• Est. primary completion date: October 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients 18 years or above at the time of inclusion;

2. Patients newly diagnosed with acute myeloid leukemia;

3. No contraindication or intolerance to any of the components of the standard chemotherapy by induction (7+3);

4. Patients able to give written informed consent.

Exclusion Criteria:

1. Patients unable to tolerate decubitus position for at least 45 minutes;

2. Any previous neoplasia or other neoplasia simultaneously;

3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;

4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before the second FLT-TEP was done.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia

Locations

Country	Name	City	State
Canada	Centre Hospitalier Universitaire de Sherbrooke	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.		September 2015